News >

ctDNA Provides Prognostic and Predictive Value in Early-Stage Breast Cancer

Caroline Seymour
Published: Friday, Apr 03, 2020

breast cancer
Circulating tumor DNA (ctDNA) can be used as a predictive measure of response to neoadjuvant chemotherapy and inform overall prognosis in patients with early-stage breast cancer, providing information that can be used to tailor treatment, according to results of a prospective study published in the Journal of Clinical Oncology Precision Oncology.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication